<DOC>
	<DOC>NCT00458185</DOC>
	<brief_summary>This study will assess the efficacy of etanercept for the treatment of Ankylosing Spondylitis (AS).</brief_summary>
	<brief_title>Study Evaluating Etanercept in Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis, aged between 18 and 70 years of age. BASDAI greater than or equal to 40 (all scores on a scale of 0 to 100). Negative result of serum human chorionic gonadotropin (HCG) pregnancy test taken at screening in all women except those surgically sterile or at least 1 year postmenopausal. Complete ankylosis (fusion) of spine. Previous receipt of etanercept, antibody to TNFα, or other TNFα inhibitors. Use of disease modifying antirheumatic drugs (DMARDs) other than hydroxychloroquine, sulphasalazine, and methotrexate within 4 weeks of baseline. Patients treated with hydroxychloroquine, sulphasalazine, and methotrexate may continue these drugs during this study but doses must be held stable for 4 weeks before baseline examination and for the duration of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>